Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice

Addiction Biology

Volumn 18, Issue 2, 2013, Pages 252-262

  Aracil Fernández, Auxiliadora ^a,c   Almela, Pilar ^b,c   Manzanares, Jorge ^a,c  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anxiety; cannabinoid; pregabalin; topiramate; tyrosine hydroxylase; withdrawal

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID 1 RECEPTOR; MU OPIATE RECEPTOR; PREGABALIN; TOPIRAMATE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CANNABIS ADDICTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; GENE EXPRESSION REGULATION; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REARING; RECTUM TEMPERATURE; TRANSCRIPTION REGULATION; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; ANXIETY; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CANNABINOIDS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; MALE; MARIJUANA ABUSE; MICE; MODELS, ANIMAL; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; SUBSTANCE WITHDRAWAL SYNDROME; TRANSCRIPTION, GENETIC; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84874434442     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00406.x     Document Type: Article

References (51)

1. Baldwin DS, Ajel K, (2007) Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 3: 185-191. (Pubitemid 46864058)
2. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG, (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103: 2035-2044.
3. Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M, (2008) Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother 8: 479-491. (Pubitemid 351480910)
4. Bobes J, Carreno JE, Gutierrez CE, San Narciso GI, Antuna MJ, Diaz T, Fernandez JJ, Cerceda A, Alvarez CE, Marina P, Garcia-Garcia M, (2004) Study of effectiveness of craving control with topiramate in patients with substance dependence disorders. Actas Esp Psiquiatr 32: 299-306. (Pubitemid 39345422)
5. Budney AJ, Hughes JR, (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry 19: 233-238. (Pubitemid 44309479)
6. Cagetti E, Baicy KJ, Olsen RW, (2004) Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. Neuroreport 15: 207-210. (Pubitemid 41615000)
7. Castane A, Maldonado R, Valverde O, (2004) Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br J Pharmacol 142: 1309-1317. (Pubitemid 39178884)
8. Cook SA, Lowe JA, Martin BR, (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285: 1150-1156. (Pubitemid 28277913)
9. Corchero J, Oliva JM, Garcia-Lecumberri C, Martin S, Ambrosio E, Manzanares J, (2004) Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain. J Psychopharmacol 18: 54-58. (Pubitemid 38623094)
10. Crawley J, Goodwin FK, (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167-170. (Pubitemid 11225713)
11. Diana M, Melis M, Muntoni AL, Gessa GL, (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A 95: 10269-10273. (Pubitemid 28415330)
12. Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S, (2007) Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol 42: 296-300.
13. Garcia-Gutierrez MS, Manzanares J, (2010) The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. J Psychopharmacol 24: 757-765.
14. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF, (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395-1398. (Pubitemid 35340861)
15. Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B, Mikics E, Freund TF, Hajos N, (2007) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25: 2445-2456. (Pubitemid 46625912)
16. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW, (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158-170. (Pubitemid 38068026)
17. Haney M, Hart CL, Ward AS, Foltin RW, (2003) Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 165: 157-165. (Pubitemid 36056992)
18. Huang P, Liu-Chen LY, Kirby LG, (2010) Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci Lett 475: 165-168.
19. Huang P, Liu-Chen LY, Unterwald EM, Cowan A, (2009) Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neurosci Lett 465: 66-70.
20. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R, (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125: 1567-1577. (Pubitemid 28548570)
21. Johnson BA, (2004) An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin Pharmacother 5: 1943-1955. (Pubitemid 39236596)
22. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ, (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61: 905-912. (Pubitemid 39181080)
23. Kouri EM, Pope HG, Jr, (2000) Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 8: 483-492.
24. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH, (2007) Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 31: 604-611. (Pubitemid 46434897)
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
26. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA, (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20: 287-294. (Pubitemid 29301682)
27. Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, Di Giannantonio M, Pozzi G, Bria P, Janiri L, (2009) Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol (Oxf) 24: 1367-1374.
28. Martinotti G, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P, (2008) Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 25: 608-618.
29. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC, (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67: 771-782. (Pubitemid 43946184)
30. Navarro M, Chowen J, Rocio ACM, del Arco I, Villanua MA, Martin Y, Roberts AJ, Koob GF, de Fonseca FR, (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9: 3397-3402. (Pubitemid 28566119)
31. Nestler EJ, (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119-128. (Pubitemid 33673366)
32. Niehaus JL, Cruz-Bermudez ND, Kauer JA, (2009) Plasticity of addiction: a mesolimbic dopamine short-circuit? Am J Addict 18: 259-271.
33. Oliva JM, Ortiz S, Palomo T, Manzanares J, (2003) Behavioural and gene transcription alterations induced by spontaneous cannabinoid withdrawal in mice. J Neurochem 85: 94-104. (Pubitemid 36389699)
34. Oliva JM, Ortiz S, Palomo T, Manzanares J, (2004) Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain. J Psychopharmacol 18: 59-65. (Pubitemid 38623095)
35. Oulis P, Masdrakis VG, Karakatsanis NA, Karapoulios E, Kouzoupis AV, Konstantakopoulos G, Soldatos CR, (2008) Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol 23: 110-112. (Pubitemid 351317284)
36. Palkovits M, (1983) Punch sampling biopsy technique. Methods Enzymol 103: 368-376.
37. Paxinos G, Franklin KBJ, (2001) The Mouse Brain in Stereotaxic Coordinates. New York: Academic Press. Harcourt Science and Technology Company.
38. Reis AD, Castro LA, Faria R, Laranjeira R, (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30: 132-135. (Pubitemid 351955879)
39. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F, (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054. (Pubitemid 27443612)
40. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA, (1994) Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33-40.
41. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, Fernandez-Ruiz JJ, Ramos JA, (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308. (Pubitemid 28447177)
42. Rubio G, Martinez-Gras I, Manzanares J, (2009) Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 29: 584-589.
43. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F, (2004) Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37: 37-40. (Pubitemid 38230738)
44. Selak I, (2001) Pregabalin (Pfizer). Curr Opin Investig Drugs 2: 828-834.
45. Spanagel R, Weiss F, (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22: 521-527. (Pubitemid 29481853)
46. Spiga S, Lintas A, Migliore M, Diana M, (2010) Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence. Addict Biol 15: 266-276.
47. Tanda G, Pontieri FE, Di Chiara G, (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050. (Pubitemid 27443611)
48. Taylor CP, Angelotti T, Fauman E, (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73: 137-150. (Pubitemid 46329329)
49. Tsou K, Patrick SL, Walker JM, (1995) Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280: R13-R15.
50. Urigüen L, Pérez-Rial S, Ledent C, Palomo T, Manzanares J, (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973. (Pubitemid 38471950)
51. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J, (2004) Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc) 40: 603-619. (Pubitemid 39281177)